secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mirum Pharmaceuticals, Inc. (MIRM)
CIK:        0001759425
Form:       8-K
Filed at:   2026-01-26T23:59:59+00:00
Accession:  0001193125-26-022582
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 2.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mirum acquires Bluejay for $280.8M cash + stock; adds late-stage HDV therapy
----------------------------------------------------------------------------

- Upfront consideration $280.8M cash plus ~4.67M shares; holdback $25.8M plus ~0.52M shares; up to $200M milestones.
- Added brelovitug (anti-HDV mAb) with FDA Breakthrough Therapy and EMA PRIME; Phase 3 AZURE topline data expected 2H 2026.
- Concurrent private placements raised ~$268.5M gross proceeds to support brelovitug development and commercial activities.
- Mirum also acquired Bluejay's net cash of ~$56.6M.
- Entities affiliated with Frazier Life Sciences (board member >5% holder) received pro rata portion of consideration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759425/000119312526022582/0001193125-26-022582-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759425/000119312526022582/d35336d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-022582

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer